Moderna got some things wrong in its development and commercialization of Spikevax for COVID-19, CEO Stéphane Bancel said during the firm’s presentation on 13 January at the J.P. Morgan Healthcare Conference in San Francisco. But the company is still looking ahead rather than dwelling on the past, especially as it builds out its late-stage pipeline and plots out how it will work with the incoming US presidential administration.
CEO Bancel Says Moderna Was ‘Too Logical’ On COVID-19 Vaccinations
Company Sees Lower Sales In 2025
The chief exec said Moderna plans to work with the incoming Trump administration, but implied hope that US regulatory agencies would heed the scientific consensus on vaccines and focus on risk-benefit.
More from J.P. Morgan
More from Business
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.